Kath. St. Paulus GmbH

At Kath. St. Paulus GmbH in Dortmund, clinical research in cardiovascular diseases focuses on major conditions such as atherosclerotic cardiovascular disease, acute myocardial infarction, atrial fibrillation, and heart failure. These studies are designed to test new approaches for lowering cardiovascular risk, preventing recurrent events, and improving treatment effectiveness in high-risk patients.

• Reducing the risk of heart attack, stroke, and other major cardiovascular events
• Evaluating therapies for patients with elevated Lp(a), obesity, or established cardiovascular disease
• Improving care for atrial fibrillation and inflammation-related heart conditions

Overall, this area reflects a strong emphasis on prevention and better long-term outcomes for people with serious heart and blood vessel disorders.

The site also has a major focus on hematologic diseases, including acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, and Waldenström’s macroglobulinemia. Research in this field is aimed at improving survival, deepening treatment responses, and finding more effective ways to control aggressive blood cancers.

• Testing new treatment combinations for leukemia and lymphoma
• Assessing response depth and minimal residual disease in multiple myeloma
• Exploring better strategies for high-risk and relapsed blood cancers

These trials highlight an active effort to refine therapy for complex malignancies of the blood and lymphatic system.

Oncology research at Kath. St. Paulus GmbH covers several solid tumors, especially breast cancer and colorectal cancer. The studies include patients with early-stage, locally advanced, metastatic, and high-risk disease, with the goal of improving disease control, reducing recurrence, and identifying more effective treatment options after surgery or standard therapy.

• Investigating new therapies for breast cancer, including HER2-positive and triple-negative disease
• Evaluating adjuvant approaches for colorectal cancer after tumor resection
• Studying treatment strategies for patients at high risk of relapse or residual disease

This oncology portfolio shows a clear interest in improving outcomes for cancers where recurrence risk remains a major challenge.

Research in immune system diseases at this hospital includes studies that address inflammation-related conditions and immune-modulating treatment approaches. The work is closely linked with cardiovascular and cancer research, reflecting a broader interest in how immune pathways influence disease progression and treatment response.

• Targeting inflammatory mechanisms that contribute to cardiovascular risk
• Exploring immune-based strategies to improve treatment effectiveness
• Assessing therapies that may reduce disease complications through immune pathway modulation

These trials support a growing role for immune-focused research in both chronic disease prevention and advanced therapy development.

The site’s research in nutritional and metabolic diseases includes obesity, overweight, type 2 diabetes, and related metabolic risk conditions. The clinical trials are aimed at lowering cardiovascular complications, improving metabolic health, and supporting better long-term management of patients with overlapping cardiometabolic disorders.

• Testing treatments for obesity and overweight in people at high cardiovascular risk
• Evaluating therapies for type 2 diabetes with heart and kidney risk
• Studying ways to reduce complications linked to metabolic disease

These studies underline the close connection between metabolism, body weight, and cardiovascular outcomes in modern clinical research.

Clinical trials in metabolism at Kath. St. Paulus GmbH examine biological pathways tied to lipoprotein disorders, elevated Lp(a), and broader cardiometabolic risk. The purpose is to better understand how metabolic factors drive disease and to test therapies that may improve prevention in patients with established risk.

• Studying Lp(a)-lowering strategies to reduce cardiovascular events
• Assessing therapies that influence lipid-related and metabolic risk factors
• Supporting prevention-focused research in patients with high baseline risk

This area connects laboratory-based metabolic insights with practical efforts to lower future disease burden.